Cephaloglycin
Kafocin (cephaloglycin) is a small molecule pharmaceutical. Cephaloglycin was first approved as Kafocin on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cephaloglycin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KAFOCIN | Eli Lilly | N-050219 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Surgical wound infection | D013530 | 1 | 1 | 1 | 2 | 1 | 6 | ||
| Infections | D007239 | EFO_0000544 | 1 | 1 | 1 | 1 | 1 | 4 | |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | — | 3 | — | 4 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 1 | — | 1 | 1 | 3 |
| Staphylococcal infections | D013203 | A49.01 | — | 1 | 1 | 1 | — | 2 | |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | 1 | — | 2 |
| Infectious arthritis | D001170 | EFO_1001351 | M00 | 1 | — | — | 1 | — | 2 |
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | — | — | 1 | — | 1 |
| Abscess | D000038 | EFO_0003030 | — | — | — | 1 | — | 1 | |
| Folliculitis | D005499 | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nasal obstruction | D015508 | HP_0001742 | — | — | 1 | — | — | 1 | |
| Nasal surgical procedures | D059747 | — | — | 1 | — | — | 1 | ||
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | 1 | — | — | 1 |
| Sick sinus syndrome | D012804 | EFO_0004275 | I49.5 | — | — | 1 | — | — | 1 |
| Syncope | D013575 | HP_0001279 | G90.01 | — | — | 1 | — | — | 1 |
| Heart block | D006327 | I45.89 | — | — | 1 | — | — | 1 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | 1 | — | — | 1 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | — | — | 1 |
| Urinary bladder neoplasms | D001749 | C67 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | — | — | 1 |
| Skin diseases | D012871 | L00-L99 | — | 1 | — | — | — | 1 | |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | — | — | 1 |
| Genetic skin diseases | D012873 | — | 1 | — | — | — | 1 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | — | — | — | 1 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Male breast neoplasms | D018567 | — | 1 | — | — | — | 1 | ||
| Genetic predisposition to disease | D020022 | — | 1 | — | — | — | 1 | ||
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
| Respiratory tract infections | D012141 | J06.9 | 3 | — | — | — | — | 3 | |
| Pyomyositis | D052880 | EFO_1001409 | M60.0 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CEPHALOGLYCIN |
| INN | cefaloglycin |
| Description | Cefaloglycin is a cephalosporin antibiotic containing at the 7beta-position of the cephem skeleton an (R)-amino(phenyl)acetamido group. It has a role as an antimicrobial agent. It is a cephalosporin and a beta-lactam antibiotic allergen. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1 |
Identifiers
| PDB | — |
| CAS-ID | 3577-01-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200971 |
| ChEBI ID | 34613 |
| PubChem CID | 19150 |
| DrugBank | DB00689 |
| UNII ID | HD2D469W6U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 209 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,324 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more